NEUROCRINE BIOSCIENCES INC
For the period ended Nov 2, 2026. Filed Nov 2, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 2, 2026 · Filed Nov 2, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · TABLE 3 (CONTINUED)
TABLE 3 (CONTINUED)
- Includes the following expenses:
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Milestones (R&D) | $10.0 | $1.0 | $32.9 | $61.5 |
| Acquired in-process research and development (IPR&D) | $11.7 | $0.3 | $34.4 | $0.4 |
Relates to the acceleration of vesting of equity awards for Soleno employees which vested in full upon the closing of the transaction.
Relates to amortization expense associated with recording approximately $168 million of VYKAT XR inventory fair value step-up.
Primarily relates to amortization of acquired intangible assets associated with the recording of approximately $2.2 billion of intellectual property related to VYKAT XR, which will be amortized over 16 years.
Reflects a pre-tax gain, net of transaction costs, recognized on the sale of Neurocrine Group Limited in January 2026.
Reflects periodic fluctuations in the fair values of equity investments.
Reflects non-cash interest expense related to the Company's credit facility, legacy campus facility costs, net of sublease income, and other immaterial costs that management does not consider indicative of the Company's ongoing operating performance.
Estimated income tax effect of Non-GAAP reconciling items are calculated using applicable statutory tax rates, taking into consideration any valuation allowance. In addition, Non-GAAP tax expense may also be affected by certain non-recurring, non-operating, or discrete tax items.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.